Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue ...
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across ...
Hall, MD, professor and chair of radiation oncology at the Medical College of Wisconsin and medical director of Froedtert ...
Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma. In an interview with CancerNetwork® at the 2026 American Society for ...
Intensity-modulated proton therapy (IMPT) allows radiation oncologists to limit the dose to organs surrounding the prostate. That property may be particularly relevant for patients with prostate ...
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence ...
Most of the KRAS inhibitors that have produced clinical data in biliary tract cancer so far target KRAS G12C, a mutation found in only a minority of patients with KRAS-mutant dise ...
Following the FDA approval of lirafugratinib (Lyrfigtu) for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma, there are currently 3 FGFR2 inhibi ...
Resection combined with cesium-131 collagen tile-based radiation therapy (TBRT; GammaTile) significantly improved time to ...
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results